Session Information
Date: Thursday, June 23, 2016
Session Title: Neuropharmacology
Session Time: 12:00pm-1:30pm
Location: Exhibit Hall located in Hall B, Level 2
Objective: To study the possibility of using levodopa and amantadine for the treatment of motor disorders in ischemic stroke after taking the standard treatment.
Background: We haven’t found clinical researches by PubMed, where influence on extrapyramidal system leads to palliating of pyramidal insufficiency.
Methods: 94 patients with ischemic stroke and dysfunction of 8-14 points by NIHSS and paresis with muscle strength 2-5 points by Oxford Scale were under our observation in the Department of Neurology of TMA, during October 2015. All of the patients received standard treatment and on its background they were identified a weak regression of neurological deficit, due to which patients were assigned to dopaminergic therapy. The patients were divided into 4 groups so as to ensure comparability of the obtained results: (1) 23 patients took only standard treatment with weak regression of neurological deficit, (2) 25 patients took amantadine 200 mg/day, (3) 23 patients – levodopa 125 mg/day, (4) 23 patients took both amantadine 200 mg/day and levodopa 125 mg/day after standard treatment.
Results: The decrease of neurological deficit (decrease of NIHSS – difference before and after treatment – to 3 points and more) amounted to 30,4%(7), 64%(16), 73,9%(17), 87%(20) respectively to first, second, third and fourth monitoring groups. Muscle strength increased at least 1 grade up in 3 groups: second – 68%(17), third – 87%(20), fourth – 95,7%(22).
Conclusions: The improvement of neurostatus dynamics under the treatment by amantadine and levodopa is significantly higher than under standard treatment with a weak regression of neurological deficit (p <0.01). By prescribing dopaminergic medicines for treatment of pyramidal insufficiency and hence, probably, influencing on the other (extrapyramidal) pathways we may reach the restoration of skeletal muscles paresis. Levodopa and amantadine could be alternative for the treatment of motor disorders in ischemic stroke, but further researches need.
To cite this abstract in AMA style:
A. Azimov, R. Sadykov, G. Rakhimbaeva, S. Dadajonov, O. Azizova. Dopaminergic medicines are alternative drugs for treatment of motor disorders in ischemic stroke [abstract]. Mov Disord. 2016; 31 (suppl 2). https://www.mdsabstracts.org/abstract/dopaminergic-medicines-are-alternative-drugs-for-treatment-of-motor-disorders-in-ischemic-stroke/. Accessed June 14, 2025.« Back to 2016 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/dopaminergic-medicines-are-alternative-drugs-for-treatment-of-motor-disorders-in-ischemic-stroke/